Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Grace Therapeutics, Inc GRCE

Grace Therapeutics, Inc., formerly Acasti Pharma Inc., is a late-stage biopharma company with drug candidates addressing rare and orphan diseases. Its therapeutic pipeline consists of three clinical-stage drug candidates supported by an intellectual property portfolio of over 40 granted and pending patents in various jurisdictions. Its lead drug candidate, GTX-104, is a clinical-stage, novel, injectable formulation of nimodipine being developed for intravenous (IV) infusion in aneurysmal subarachnoid hemorrhage (aSAH) patients to address significant unmet medical needs. GTX-104 provides a convenient IV delivery of nimodipine in the intensive care unit, eliminating the need for nasogastric tube administration in unconscious or dysphagic patients. Its other pipeline drug candidates include GTX-102, which is an oral-mucosal betamethasone spray for the treatment of Ataxia Telangiectasia and GTX-101, which is a topical bio adhesive film-forming bupivacaine spray for Postherpetic Neuralgia.


NDAQ:GRCE - Post by User

Bullboard Posts
Comment by Rosmorducon Jun 29, 2020 9:37am
88 Views
Post# 31202266

RE:RE:RE:Science always Wins!

RE:RE:RE:Science always Wins!Iscfa,

if what you are saying is true, that the doctors at those 5 sites did not follow protocol adequately and this was the cause of this mess and FDA concurs with these findings and audits and if Trilogy 2 results will achieve the secondary end points (despite the screw-up pf those 5 labs which was no fault of Acasti), it would be a good.  


========================================================================

The design protocols are not flawed. A few dopey doctors did not follow them. e.g. start a patient on a statin and register them in the trial before 6 weeks of stabilization on the statin.   

WalkOverTheStrt wrote:If the design protocols were flawed then it will not be kept mainly to the five sites in T2. In fact it could be worse... we just don't know. The fact the company's MC is $55m is unreal for a drug that works....
 
Bullboard Posts